Trials / Completed
CompletedNCT01302990
Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Medicago · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, randomized, double-blind, active- and placebo-controlled, multicenter, dose-ranging study to evaluate the safety, tolerability and Immunogenicity of a single non-adjuvanted dose of the H1 VLP Influenza vaccine in healthy adults 18-49 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Dose given at Day 0 | Dose given by intramuscular administration (0.5 mL) |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2011-07-01
- Completion
- 2011-11-01
- First posted
- 2011-02-24
- Last updated
- 2013-08-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01302990. Inclusion in this directory is not an endorsement.